Evotec and Pfizer collaborate to advance drug discovery in France

EQS-News: Evotec SE / Key word(s): Miscellaneous
Evotec and Pfizer collaborate to advance drug discovery in France

10.07.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

__TOKEN__0__0__

     * Multi-year collaboration will initially focus on early discovery
     research for metabolic and infectious diseases

Hamburg, Germany, 10 July 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO) today announced it has entered into a multi-year master
research collaboration and option and license agreement with Pfizer. Under
the agreement, Evotec and Pfizer will initially focus on early discovery
research for metabolic and infectious diseases.

The research will be carried out at Evotec's sites in France, including
Campus Curie in Toulouse, a state-of-the-art research site with capabilities
spanning high throughput screening, in vitro and in vivo biology, proteomics
and metabolomics. Evotec will receive research support funding from Pfizer
and be eligible for potential milestones and royalties related to success of
the programs.

Dr Matthias Evers, Chief Business Officer at Evotec, commented: "We are
honoured to collaborate with Pfizer to research potential new first-in-class
therapeutic approaches. France has established a thriving biopharmaceutical
ecosystem to which Evotec also contributes with its strong presence with
more than 1,000 employees at our French sites, building a strong pipeline of
medicines that matter. Focussing on diseases with severe unmet medical need
and highly innovative therapeutic approaches, we look forward to supporting
our partners at Pfizer with integrated R&D activities."

Dr Luca Mollo, Vice President and Medical Lead France at Pfizer, commented:
"We are thrilled to collaborate with Evotec to conduct discovery research
that may help unlock new approaches to treating pervasive metabolic and
infectious diseases that impact millions of patients worldwide. France has
developed a strong biopharmaceutical ecosystem, which is why we're thrilled
to collaborate with Evotec to build on our shared commitment to advancing
scientific discovery for diseases with unmet need".

About Evotec SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec provides high value pipeline
co-creating partnerships and solutions to all Top 20 Pharma and over 800
biotechnology companies, academic institutions, as well as other healthcare
stakeholders. Evotec has strategic activities in a broad range of currently
underserved therapeutic areas, including e.g. neurology, oncology, as well
as metabolic and infectious diseases. Within these areas of expertise,
Evotec aims to create the world-leading co-owned pipeline for innovative
therapeutics and has to-date established a portfolio of more than 200
proprietary and co-owned R&D projects from early discovery to clinical
development. Evotec operates globally with more than 5,000 highly qualified
people. The Company's sites in Europe and the USA offer highly synergistic
technologies and services and operate as complementary clusters of
excellence. For additional information please go to www.evotec.com and
follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking-statements
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "should," "target," "would"
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

For further information, please contact:

Media

Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com

Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com


---------------------------------------------------------------------------

10.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1942469

End of News EQS News Service
---------------------------------------------------------------------------

1942469 10.07.2024 CET/CEST